Dec. 1, 2022 Price forecast | 2 weeks: -1.49% | 1 month: 1.42% | 3 months: 4.67%


SMFR stock forecast

Our latest prediction for GeneDx Holdings Corp's stock price was made on the Dec. 1, 2022 when the stock price was at 0.40$.

In the short term (2weeks), SMFR's stock price should underperform the market by -1.49%. During that period the price should oscillate between -10.40% and +15.58%.

In the medium term (3months), SMFR's stock price should outperform the market by 4.67%. During that period the price should oscillate between -28.06% and +34.78%.

Create a solid portfolio with SMFR

Add SMFR to your portfolio and optimize it!


About GeneDx Holdings Corp

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis™, its innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

At the moment the company generates 341M USD in revenues.

On its last earning announcement, the company reported a loss of -0.59$ per share.

The book value per share is 1.58$

GeneDx Holdings Corp website


Three months stock forecastDec. 1, 2022


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
341M -7.60% -432M -126.51% -208M -0.59 - - 381M 1.58 - - -